Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Trastuzumab Deruxtecan (DS-8201a) rispetto alla scelta dello sperimentatore per il carcinoma mammario a basso contenuto di HER2 che si è diffuso o non può essere rimosso chirurgicamente [DESTINY-Breast04]

1 settembre 2026 aggiornato da: Daiichi Sankyo

Uno studio di fase 3, multicentrico, randomizzato, in aperto, con controllo attivo di DS-8201a, un farmaco coniugato anti-HER2-anticorpo (ADC), rispetto al trattamento scelto dal medico per soggetti affetti da carcinoma mammario a basso contenuto di HER2, non resecabile e/o metastatico

This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

  • Cannot be removed by an operation
  • Has spread to other parts of the body

Panoramica dello studio

Descrizione dettagliata

This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.

The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

557

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Innsbruck, Austria, 6020
        • Medizinische Universität Innsbruck
      • Linz, Austria, 4020
        • Kepler Universitätsklinikum
      • Salzburg, Austria, 5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna, Austria, 1090
        • AKH - Medizinische Universität Wien (4305)
      • Wels, Austria, 4600
        • Klinikum Wels-Grieskirchen GmbH
      • Brussels, Belgio, 1000
        • Institut Jules Bordet
      • Brussels, Belgio, 1090
        • Universitair Ziekenhuis Brussel
      • Brussels, Belgio, 1200
        • Cliniques Universitaires Saint-Luc
      • Leuven, Belgio, 3000
        • UZ Leuven
      • Loverval, Belgio, 6280
        • Grand Hôpital de Charleroi
      • Namur, Belgio, 5000
        • CHU UCL Namur
      • Tournai, Belgio, 7500
        • Centre Hospitalier Wallonie picarde - Site IMC
    • Alberta
      • Calgary, Alberta, Canada, T2N4N2
        • Tom Baker Cancer Center
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Toronto Sunnybrook Hospital
    • Quebec
      • Montreal, Quebec, Canada, H2W 1S6
        • McGill University - Dept. Oncology Clinical Research Program
    • Anhui
      • Hefei, Anhui, Cina, 230001
        • Anhui Provincial Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100853
        • Chinese PLA General Hospital
      • Beijing, Beijing Municipality, Cina, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
    • Fujian
      • Fuzhou, Fujian, Cina, 350025
        • Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510120
        • Sun Yat-sen Memorial hospital, Sun Yat-sen University
    • Heilongjiang
      • Harbin, Heilongjiang, Cina, 150081
        • Harbin Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Cina, 430079
        • Hubei Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210008
        • The Affiliated Drum Tower Hospital of Nanjing University
    • Jilin
      • Changchun, Jilin, Cina, 130000
        • The First Hospital of Jilin University
      • Changchun, Jilin, Cina, 130012
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Cina, 110042
        • Liaoning Cancer Hospital & Institute
    • Ningxia Hui
      • Yinchuan, Ningxia Hui, Cina, 750004
        • General Hospital of Ningxia Medical University
    • Shandong
      • Linyi, Shandong, Cina, 276001
        • Linyi Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200080
        • Shanghai General Hospital
      • Shanghai, Shanghai Municipality, Cina, 20032
        • Fudan University Shanghai Cancer Center
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • West China Hospital, Sichuan University
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, Cina, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
      • Daegu, Corea del Sud, 41404
        • Kyungpook National University Chilgok Hospital
      • Seoul, Corea del Sud, 03080
        • Seoul National University Hospital
      • Seoul, Corea del Sud, 05505
        • Asan Medical Center
      • Seoul, Corea del Sud, 06351
        • Samsung Medical Center
      • Seoul, Corea del Sud, 06591
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, Corea del Sud, 120-752
        • Severance Hospital, Yonsei University Health System
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Corea del Sud, 10408
        • National Cancer Center
      • Incheon, Gyeonggi-do, Corea del Sud, 22332
        • Inha University Hospital
      • Seongnam-si, Gyeonggi-do, Corea del Sud, 13620
        • Seoul National University Bundang Hospital
      • Suwon, Gyeonggi-do, Corea del Sud, 16499
        • Ajou University Hospital
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Corea del Sud, 361-711
        • Chungbuk National University Hospital
      • Paris, Francia, 75020
        • Hopital Tenon
      • Paris, Francia, 75005
        • Institut Curie - site de Paris
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, Francia, 13009
        • Institut Paoli Calmettes
    • Calvados
      • Caen, Calvados, Francia, 14076
        • Centre François Baclesse
    • Cotes d'Armor
      • Plérin, Cotes d'Armor, Francia, 22190
        • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    • Finistere
      • Brest, Finistere, Francia, 29609
        • CHU Brest - Hôpital Morvan
    • Gironde
      • Bordeaux, Gironde, Francia, 33076
        • Institut Bergonié
    • Herault
      • Montpellier, Herault, Francia, 34070
        • Clinique Clementville
      • Montpellier, Herault, Francia, 34298
        • Institut Régional du Cancer de Montpellier
    • Ille Et Vilaine
      • Rennes, Ille Et Vilaine, Francia, 35042
        • CRLCC Eugene Marquis
    • Loire Atlantique
      • Saint-Herblain, Loire Atlantique, Francia, 44805
        • ICO - Site René Gauducheau
    • Loiret
      • Le Puy-en-Velay, Loiret, Francia, 43012
        • Centre Hospitalier Emile Roux
    • Maine Et Loire
      • Angers, Maine Et Loire, Francia, 49055
        • ICO - Site Paul Papin
    • Nord
      • Valenciennes, Nord, Francia, 59322
        • Centre Hospitalier Valenciennes
    • Paris
      • Paris, Paris, Francia, 75475
        • Hôpital Saint-Louis - Paris
    • Sarthe
      • Le Mans, Sarthe, Francia, 72015
        • Clinique Victor Hugo - Centre Jean Bernard
    • Vaculuse
      • Avignon, Vaculuse, Francia, 84918
        • Institut Sainte Catherine
    • Val De Marne
      • Saint-Mandé, Val De Marne, Francia, 94160
        • Hôpital d'Instruction des Armees Begin*
      • Villejuif, Val De Marne, Francia, 94805
        • Institut Gustave Roussy
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Germania, 69120
        • Universitaetsklinikum Heidelberg
    • Bavaria
      • Munich, Bavaria, Germania, 81377
        • Klinikum der Universitaet Muenchen - Campus Grosshardern
    • Aichi-ken
      • Nagoya, Aichi-ken, Giappone, 464-8681
        • Aichi Cancer Center Hospital
    • Chiba
      • Kashiwa-shi, Chiba, Giappone, 277-8577
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, Giappone, 791-0280
        • NHO Shikoku Cancer Center
    • Fukuoka
      • Fukuoka, Fukuoka, Giappone, 811-1395
        • NHO Kyushu Cancer Center
    • Fukushima
      • Fukushima, Fukushima, Giappone, 960-1295
        • Fukushima Medical University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Giappone, 730-8518
        • Hiroshima City Hiroshima Citizens Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Giappone, 003-0804
        • NHO Hokkaido Cancer Center
    • Hyōgo
      • Nishinomiya-shi, Hyōgo, Giappone, 663-8501
        • Hyogo College of Medicine Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Giappone, 892-0833
        • Hakuaikai Sagara Hospital
    • Kanagawa
      • Isehara, Kanagawa, Giappone, 259-1193
        • Tokai University Hospital
      • Yokohama, Kanagawa, Giappone, 241-8515
        • Kanagawa Cancer Center
    • Osaka
      • Osaka, Osaka, Giappone, 540-0006
        • NHO Osaka National Hospital
    • Osakasayama-shi
      • Onohigashi, Osakasayama-shi, Giappone, 589-8511
        • Kindai University Hospital
    • Saitama
      • Kitaadachi-gun, Saitama, Giappone, 362-0806
        • Saitama Cancer Center
    • Shizuoka
      • Sunto-gun, Shizuoka, Giappone, 411-8777
        • Shizuoka Cancer Center
    • Tokyo-To
      • Kōtoku, Tokyo-To, Giappone, 135-8550
        • Cancer Institute Hospital of JFCR
      • Minatoku, Tokyo-To, Giappone, 105-8470
        • Toranomon Hospital
      • Shinagawa-Ku, Tokyo-To, Giappone, 142-8666
        • Showa University Hospital
      • Athens, Grecia, 15125
        • Athens Medical Center
      • Athens, Grecia, 11528
        • General Hospital of Athens "Alexandra"
      • Athens, Grecia, 14564
        • General Oncology Hospital of Kifissia " Agioi Anargyroi"
      • Heraklion, Grecia, 71110
        • University General Hospital of Heraklion
      • Larissa, Grecia, 41110
        • University General Hospital of Larissa
      • Thessaloniki, Grecia, 54622
        • Bioclinic Thessaloniki
      • Thessaloniki, Grecia, 54645
        • Euromedica General Clinic Thessaloniki
      • Thessaloniki, Grecia, 56429
        • General Hospital Papageorgiou
      • Thessaloniki, Grecia, 57001
        • Interbalkan Hospital of Thessaloniki
      • Haifa, Israele, 3109601
        • Rambam Health Care Center
      • Jerusalem, Israele, 9103102
        • Shaare Zedek Medical Center
      • Jerusalem, Israele, 9112001
        • Hadassah University Hospital - Ein Kerem
      • Petah Tikva, Israele, 49100
        • Rabin Medical Center-Beilinson Campus
      • Ramat Gan, Israele, 52363
        • Chaim Sheba Medical Center
      • Rehovot, Israele, 7610001
        • Kaplan Medical Center
      • Safed, Israele, 13100
        • Ziv Medical Center
      • Tel Aviv, Israele, 6423906
        • Tel Aviv Sourasky Medical Center
      • Bologna, Italia, 40138
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
      • Brescia, Italia, 25100
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
      • Catania, Italia, 95125
        • Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
      • Catanzaro, Italia, 88100
        • Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
      • Milan, Italia, 20141
        • IEO Istituto Europeo di Oncologia
      • Naples, Italia, 80131
        • Istituto Nazionale Tumori Fondazione G. Pascale
      • Rimini, Italia, 47923
        • Ospedale degli Infermi
      • Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Roma, Italia, 00133
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    • Lecce
      • Tricase, Lecce, Italia, 73039
        • Azienda Ospedaliera Card. G. Panico
    • Milano
      • Monza, Milano, Italia, 20900
        • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
      • Rozzano, Milano, Italia, 20089
        • Istituto Clinico Humanitas
    • Verona
      • Negrar, Verona, Italia, 37024
        • Ospedale Sacro Cuore Don Calabria
      • Braga, Portogallo, 4710-243
        • Hospital de Braga
      • Guimarães, Portogallo, 4835-044
        • Centro Hospitalar do Alto do Ave, EPE
      • Lisbon, Portogallo, 1649-035
        • Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Lisbon, Portogallo, 1400-038
        • Fundação Champalimaud
      • Matosinhos Municipality, Portogallo, 4464-509
        • Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
      • Porto, Portogallo, 4200-072
        • Instituto Português de Oncologia do Porto Francisco Gentil, EPE
      • Porto, Portogallo, 4099-001
        • Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
      • Santa Maria da Feira, Portogallo, 4520-211
        • Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
      • Vila Nova de Gaia, Portogallo, 4434-502
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
      • Vila Real, Portogallo, 5000-508
        • Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
    • Cornwall
      • Truro, Cornwall, Regno Unito, TR1 3LJ
        • Royal Cornwall Hospital
    • Greater London
      • London, Greater London, Regno Unito, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, Regno Unito, EC1M 6BQ
        • Queen Mary University of London
      • London, Greater London, Regno Unito, NW1 2PG
        • University College London Hospitals
    • Lothian Region
      • Edinburgh, Lothian Region, Regno Unito, EH4 2XU
        • Western General Hospital
    • Nottinghamshire
      • Nottingham, Nottinghamshire, Regno Unito, NG5 1PB
        • Nottingham University Hospitals City Campus
    • Surrey
      • Guildford, Surrey, Regno Unito, GU2 7XX
        • Royal Surrey County Hospital
      • Moscow, Russia, 115478
        • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
      • Moscow, Russia, 143423
        • SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
      • Yaroslavl, Russia, 150054
        • SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
      • Barcelona, Spagna, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Spagna, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Spagna, 08023
        • Hospital Quironsalud Barcelona
      • Barcelona, Spagna, 08003
        • Hospital del Mar
      • Madrid, Spagna, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spagna, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, Spagna, 28034
        • Hospital Ruber Internacional
      • Madrid, Spagna, 28033
        • MD Anderson Cancer Centre
      • Málaga, Spagna, 29010
        • Hospital Clinico Universitario Virgen de la Victoria
      • Seville, Spagna, 41009
        • Hospital Universitario Virgen Macarena
      • Seville, Spagna, 41013
        • Hospital Universitario Virgen del Rocio
      • Valencia, Spagna, 46014
        • Hospital General Universitario de Valencia
      • Valencia, Spagna, 46009
        • Instituto Valenciano de Oncologia IVO
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spagna, 08908
        • ICO l'Hospitalet - Hospital Duran i Reynals
    • Guipuzcoa
      • San Sebastián, Guipuzcoa, Spagna, 20014
        • Hospital Universitario Donostia
    • La Coruña
      • A Coruña, La Coruña, Spagna, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Tenerife
      • San Cristóbal de La Laguna, Tenerife, Spagna, 38320
        • Hospital Universitario de Canarias
    • Vizcaya
      • Bilbao, Vizcaya, Spagna, 48013
        • Hospital de Basurto
    • Arizona
      • Chandler, Arizona, Stati Uniti, 85224
        • Ironwood Cancer & Research Centers - Chandler II
      • Gilbert, Arizona, Stati Uniti, 85234
        • Banner MD Anderson Cancer Center
      • Goodyear, Arizona, Stati Uniti, 85338
        • Cancer Treatment Centers of America at Western Regional Medical Center
    • California
      • Los Angeles, California, Stati Uniti, 90095
        • UCLA School of Medicine
      • Palo Alto, California, Stati Uniti, 94305
        • Stanford Cancer Institute
      • Redondo Beach, California, Stati Uniti, 90277
        • Cancer Care Associates Medical Group, Inc. TORI
      • San Francisco, California, Stati Uniti, 94158
        • University of California at San Francisco (PARENT)
    • Connecticut
      • Norwich, Connecticut, Stati Uniti, 06360
        • Eastern Connecticut Hematology/Oncology Assoc.
    • Delaware
      • Newark, Delaware, Stati Uniti, 19713
        • Christiana Care Health Services, Inc.
    • Florida
      • Boca Raton, Florida, Stati Uniti, 33426
        • Sylvester Comprehensive Cancer Center - Deerfield Beach
      • Fort Myers, Florida, Stati Uniti, 33916
        • Florida Cancer Specialists (South Region)
      • Hollywood, Florida, Stati Uniti, 33021
        • Memorial Healthcare System MRH Cancer Center
      • Orlando, Florida, Stati Uniti, 32806
        • Orlando Health, Inc.
      • Tampa, Florida, Stati Uniti, 33139
        • Moffitt Cancer Center -Tampa
    • Georgia
      • Newnan, Georgia, Stati Uniti, 30263
        • Cancer Treatment Centers of America-Georgia
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • University of Chicago Medical Center
      • Zion, Illinois, Stati Uniti, 60099
        • Cancer Treatment Centers of America
    • Kansas
      • Wichita, Kansas, Stati Uniti, 67214
        • Cancer Center of Kansas
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70115
        • Touro Infirmary
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Henry Ford Hospital
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Saint Luke's Hospital of Kansas City
    • New Jersey
      • Livingston, New Jersey, Stati Uniti, 07039
        • Saint Barnabas Medical Center
    • New York
      • New York, New York, Stati Uniti, 10016
        • New York University Medical Center
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Hospital
      • New York, New York, Stati Uniti, 10065
        • Weill Cornell Medicine Breast Center
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15212
        • Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Stati Uniti, 15219
        • University of Pittsburgh Medical Center Health System
    • South Carolina
      • Greenville, South Carolina, Stati Uniti, 29601
        • St Francis Hospital
    • Tennessee
      • Knoxville, Tennessee, Stati Uniti, 37909
        • Brig Center for Cancer Care and Survivorship
      • Memphis, Tennessee, Stati Uniti, 38120
        • Baptist Cancer Center
      • Nashville, Tennessee, Stati Uniti, 37201
        • Tennessee Oncology - Skyline Satellite
    • Texas
      • Dallas, Texas, Stati Uniti, 75234
        • BloomTrials Clinical Research, LLC
      • Houston, Texas, Stati Uniti, 77030
        • The Methodist Hospital Research Institute
      • Houston, Texas, Stati Uniti, 77030
        • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Virginia Cancer Specialists
      • Solna, Svezia, 17176
        • Karolinska universitetssjukhuset - Solna
      • Sundsvall, Svezia, 85186
        • Länssjukhuset Sundsvall-Härnösand
      • Uppsala, Svezia, 75185
        • Akademiska Sjukhuset
      • Aarau, Svizzera, 5000
        • Hirslanden Medical Center
      • Basel, Svizzera, 4031
        • Universitaetsspital Basel
      • Chur, Svizzera, 7000
        • Kantonsspital Graubuenden
      • Lausanne, Svizzera, 1011
        • Centre Hospitalier Universitaire Vaudois
      • Sankt Gallen, Svizzera, 9007
        • Kantonsspital St. Gallen
      • Winterthur, Svizzera, 8401
        • Kantonsspital Winterthur
      • Zurich, Svizzera, 8091
        • Universitaetsspital Zuerich
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital
      • Budapest, Ungheria, 1097
        • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
      • Budapest, Ungheria, 1122
        • Orszagos Onkologiai Intezet
      • Debrecen, Ungheria, 4032
        • Debreceni Egyetem
      • Gyula, Ungheria, 5700
        • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
      • Nyíregyháza, Ungheria, 4400
        • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
      • Szolnok, Ungheria, 5004
        • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Is the age of majority in their country

  • Has pathologically documented breast cancer that:

    1. Is unresectable or metastatic
    2. Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
    3. Is HR-positive or HR-negative
    4. Has progressed on, and would no longer benefit from, endocrine therapy
    5. Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
    6. Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
  • Has documented radiologic progression (during or after most recent treatment)

  • Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:

    1. assessment of HER2 status
    2. assessment of post-treatment status
  • Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1

  • Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions

  • Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion Criteria:

  • Is ineligible for all options in the physician's choice arm
  • Has breast cancer ever assessed with high-HER2 expression
  • Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
  • Has uncontrolled or significant cardiovascular disease
  • Has spinal cord compression or clinically active central nervous system metastases
  • Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Trastuzumab deruxtecan

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a

DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

Altri nomi:
  • DS-8201a
Comparatore attivo: Physician's Choice

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:

  • Capecitabine
  • Eribulin
  • Gemcitabine
  • Paclitaxel
  • Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Lasso di tempo: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Numero di eventi di sopravvivenza complessiva (morti)
Lasso di tempo: Dalla data di randomizzazione fino alla data di morte per qualsiasi causa, fino a circa 3 anni
Dalla data di randomizzazione fino alla data di morte per qualsiasi causa, fino a circa 3 anni
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Lasso di tempo: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Lasso di tempo: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Lasso di tempo: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Lasso di tempo: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Overall Survival (OS) in All Patients
Lasso di tempo: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Lasso di tempo: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Lasso di tempo: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Lasso di tempo: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Lasso di tempo: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
All-Cause Mortality
Lasso di tempo: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Global Clinical Leader, Daiichi Sankyo

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 dicembre 2018

Completamento primario (Effettivo)

11 gennaio 2022

Completamento dello studio (Effettivo)

19 maggio 2026

Date di iscrizione allo studio

Primo inviato

6 novembre 2018

Primo inviato che soddisfa i criteri di controllo qualità

6 novembre 2018

Primo Inserito (Effettivo)

7 novembre 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Periodo di condivisione IPD

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Criteri di accesso alla condivisione IPD

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi